Breaking Finance News

A statement released earlier today by BTIG about Vericel (NASDAQ:VCEL) bumps the target price to $6.00

Boasting a price of $2.70, Vericel (NASDAQ:VCEL) traded 3.41% higher on the day. With the last stock price close down 47.62% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Vericel has recorded a 50-day average of $3.72 and a two hundred day average of $3.08. Volume of trade was down over the average, with 349,660 shares of VCEL changing hands under the typical 491,428

BTIG bumped up the target of Vericel (NASDAQ:VCEL) to $6.00 stating a potential upside of 1.22%.

Performance Chart

Vericel (NASDAQ:VCEL)

With a total market value of $0, Vericel has 52 week low of $2.00 and a 52 week high of $4.70 .

In addition to BTIG reporting its target price, a total of 2 brokers have issued a report on the stock. The consensus target price is $11.72 with 1 broker rating the stock a strong buy, 2 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Vericel (NASDAQ:VCEL)

Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *